First truly biocompatible MIGS implant from iSTAR Medical shows consistently outstanding efficacy in patients with glaucoma
Two-year final results from STAR-I trial and initial data from STAR-II European trial tout MINIjectTM as a highly promising treatment.
WAVRE, Belgium — 29 April 2020: iSTAR Medical SA, a clinical-stage medical device company pioneering truly biocompatible solutions for glaucoma, today announced positive results from two clinical trials of its micro-invasive glaucoma surgery (MIGS) implant MINIject. Both studies showed consistently outstanding reduction of intraocular pressure (IOP) and reduced need for IOP-lowering medication in over 50 patients with open angle glaucoma, following standalone MINIject implantation.